Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 390 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Open Angle-glaucoma Clear all
Recruiting Phase 3 Interventional

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852
View directory record Official record
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dothan, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 13, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Drug Delivery System in Glaucoma

NCT01016691
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 13, 2026, 5:35 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases

NCT07780890
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dysfunction, Open Angle Glaucoma (OAG), Dry Eye Disease (DED), Keratoconus, Lasik Eye Surgery
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 79 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 13, 2026, 5:35 AM EDT
Recruiting Not applicable Interventional

Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma

NCT07220876
View directory record Official record
Conditions
Open Angle Glaucoma (OAG)
Interventions
VisiPlate Glaucoma Implant
Device
Lead sponsor
Avisi Technologies Inc.
Industry
Eligibility
45 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Glendale, Arizona • Sacramento, California • Grand Junction, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 13, 2026, 5:35 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of PER-001 in Participants With Open-Angle Glaucoma

NCT05822245
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham
Drug
Lead sponsor
Perfuse Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 13, 2026, 5:35 AM EDT
Recruiting No phase listed Observational

DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma

NCT06933836
View directory record Official record
Conditions
Open Angle Glaucoma (OAG)
Interventions
DSLT enables newly diagnosed patients to remain well controlled and off medications
Device
Lead sponsor
Barnet Dulaney Perkins Eye Centers
Network
Eligibility
30 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 13, 2026, 5:35 AM EDT
Terminated Not applicable Interventional Results available

Post Approval Study of the CyPass System

NCT03273907
View directory record Official record
Conditions
Primary Open-angle Glaucoma, Cataract
Interventions
CyPass Micro-Stent implanted with CyPass 241-S applier, Cataract surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
Phoenix, Arizona • Orange, California • Fort Collins, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Sep 13, 2026, 5:35 AM EDT
Recruiting Not applicable Interventional

Electrical Stimulation for Vision Neuroenhancement in Glaucoma

NCT06685211
View directory record Official record
Conditions
Glaucoma, Glaucoma Open-Angle
Interventions
Eyetronic rtACS, Sham rtACS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 13, 2026, 5:35 AM EDT
Completed Phase 1 Interventional

Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

NCT03488550
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
ANX007
Biological
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 13, 2026, 5:35 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

NCT04396002
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Life Space Questionnaire, Low Luminance Questionnaire, Contrast sensitivity under dim illumination, Visual field under dim illumination (MAIA), Macular Pigment Optical Density (MPOD), Dark Adaptation
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 13, 2026, 5:35 AM EDT
Completed Phase 4 Interventional Results available

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT01253902
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
bimatoprost ophthalmic solution 0.01%, travoprost ophthalmic solution 0.004%, latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 13, 2026, 5:35 AM EDT
Terminated Phase 1 Interventional

Safety Study of Latanoprost Slow Release Insert

NCT01180062
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Latanoprost, Arm 2, Latanoprost SR insert
Drug
Lead sponsor
Daniel Moore
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 13, 2026, 5:35 AM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 13, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

NCT05451329
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 13, 2026, 5:35 AM EDT
Terminated No phase listed Observational

Assessing Ocular Hemodynamic Response to Surgical Intervention in Glaucoma

NCT02891317
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Low Tension Glaucoma, Cataract, Ocular Hypertension
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 13, 2026, 5:35 AM EDT
Not listed Not applicable Interventional

A Single Center Proof Of Concept Study To Assess Intra And Perioperative Safety Profile Of OMNI Surgical System

NCT04530084
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
OMNI Surgical System
Device
Lead sponsor
Mark Gallardo, MD
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 13, 2026, 5:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years to 99 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 13, 2026, 5:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

visuALL Field Analyzer (vFA) Compared to Standard Humphrey Automated Perimetry

NCT03804684
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Standard Automatic Perimetry Humphrey Field Analyzer, visuALL Field Analyzer
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
21 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 13, 2026, 5:35 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Hydrus Microstent as a Quality of Life Consideration

NCT05955118
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Hydrus Microstent
Device
Lead sponsor
InSight Vision Center Medical Group, Inc
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 13, 2026, 5:35 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy

NCT02984813
View directory record Official record
Conditions
Open-angle Glaucoma, Diabetic Retinopathy
Interventions
GlaucoHealth, GlaucoSelect, Placebo
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 13, 2026, 5:35 AM EDT
Completed Phase 3 Interventional

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

NCT00277498
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Xalacom, Xalatan, Timolol
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
64
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Artesia, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 13, 2026, 5:35 AM EDT
Completed Not applicable Interventional Results available

Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent

NCT04629521
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Cataract
Interventions
CyPass Micro-Stent, Cataract Surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Glendale, Arizona • Orange, California • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 13, 2026, 5:35 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension

NCT01520116
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3, Stage 1 - ATS907 - Dose 4, Stage 1 - Vehicle, Stage 2 - ATS907 - Dose A - to be selected based on Stage 1, Stage 2 - ATS907 - Dose B - to be selected based on Stage 1, Timoptic
Drug
Lead sponsor
Altheos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
Artesia, California • Glendale, California • Saint Joseph, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 13, 2026, 5:35 AM EDT
Completed Phase 2 Interventional

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT02136940
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2015 · Synced Sep 13, 2026, 5:35 AM EDT